Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design

Pascal Amedro, Arthur Gavotto, Hamouda Abassi, Marie-Christine Picot, Stefan Matecki, Sophie Malekzadeh-Milani, Marilyne Levy, Magalie Ladouceur, Caroline Ovaert, Philippe Aldebert, Jean-Benoit Thambo, Alain Fraisse, Marc Humbert, Sarah Cohen, Alban-Elouen Baruteau, Clement Karsenty, Damien Bonnet, Sebastien Hascoet, SV-INHIBITION study investigators, Pascal Amedro, Arthur Gavotto, Hamouda Abassi, Marie-Christine Picot, Stefan Matecki, Sophie Malekzadeh-Milani, Marilyne Levy, Magalie Ladouceur, Caroline Ovaert, Philippe Aldebert, Jean-Benoit Thambo, Alain Fraisse, Marc Humbert, Sarah Cohen, Alban-Elouen Baruteau, Clement Karsenty, Damien Bonnet, Sebastien Hascoet, SV-INHIBITION study investigators

Abstract

Aims: In univentricular hearts, selective lung vasodilators such as phosphodiesterase type 5 (PDE5) inhibitors would decrease pulmonary resistance and improve exercise tolerance. However, the level of evidence for the use of PDE5 inhibitors in patients with a single ventricle (SV) remains limited. We present the SV-INHIBITION study rationale, design, and methods.

Methods and results: The SV-INHIBITION trial is a nationwide multicentre, randomized, double blind, placebo-controlled, Phase III study, aiming to evaluate the efficacy of sildenafil on the ventilatory efficiency during exercise, in teenagers and adult patients (>15 years old) with an SV. Patients with a mean pulmonary arterial pressure >15 mmHg and a trans-pulmonary gradient >5 mmHg, measured by cardiac catheterization, will be eligible. The primary outcome is the variation of the VE/VCO2 slope, measured by a cardiopulmonary exercise test, between baseline and 6 months of treatment. A total of 50 patients are required to observe a decrease of 5 ± 5 points in the VE/VCO2 slope, with a power of 90% and an alpha risk of 5%. The secondary outcomes are clinical outcomes, oxygen saturation, 6 min walk test, SV function, NT-proBNP, peak VO2 , stroke volume, mean pulmonary arterial pressure, trans-pulmonary gradient, SF36 quality of life score, safety, and acceptability.

Conclusions: The SV-INHIBITION study aims to answer the question whether PDE5 inhibitors should be prescribed in patients with an SV. This trial has been built focusing on the three levels of research defined by the World Health Organization: disability (exercise tolerance), deficit (SV function), and handicap (quality of life).

Trial registration: ClinicalTrials.gov NCT03997097.

Keywords: Congenital heart defect; Exercise capacity; Pulmonary hypertension; Pulmonary vasodilator; Sildenafil; Single ventricle.

Conflict of interest statement

None declared.

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Figures

Figure 1
Figure 1
Flow chart.

References

    1. Gewillig M, Brown SC. The Fontan circulation after 45 years: update in physiology. Heart 2016; 102: 1081–1086.
    1. Amedro P, Gavotto A, Guillaumont S, Bertet H, Vincenti M, De La Villeon G, Bredy C, Acar P, Ovaert C, Picot MC, Matecki S. Cardiopulmonary fitness in children with congenital heart diseases versus healthy children. Heart 2018; 104: 1026–1036.
    1. Goldstein BH, Urbina EM, Khoury PR, Gao Z, Amos MA, Mays WA, Redington AN, Marino BS. Endothelial function and arterial stiffness relate to functional outcomes in adolescent and young adult Fontan survivors. J Am Heart Assoc 2016; 5.
    1. Oldenburger NJ, Mank A, Etnel J, Takkenberg JJ, Helbing WA. Drug therapy in the prevention of failure of the Fontan circulation: a systematic review. Cardiol Young 2016; 26: 842–850.
    1. Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, Gewillig M, Mertens L. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young 2009; 19: 331–339.
    1. Mori H, Park IS, Yamagishi H, Nakamura M, Ishikawa S, Takigiku K, Yasukochi S, Nakayama T, Saji T, Nakanishi T. Sildenafil reduces pulmonary vascular resistance in single ventricular physiology. Int J Cardiol 2016; 221: 122–127.
    1. Castaldi B, Bordin G, Padalino M, Cuppini E, Vida V, Milanesi O. Hemodynamic impact of pulmonary vasodilators on single ventricle physiology. Cardiovasc Ther 2018; 36.
    1. Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E, Hanseus K, Sørensen KE, Søndergaard L. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (treatment with endothelin receptor antagonist in Fontan patients, a randomized, placebo‐controlled, double‐blind study measuring peak oxygen consumption) study. Circulation 2014; 130: 2021–2030.
    1. Hill KD, Tunks RD, Barker PC, Benjamin DK Jr, Cohen‐Wolkowiez M, Fleming GA, Laughon M, Li JS. Sildenafil exposure and hemodynamic effect after stage II single‐ventricle surgery. Pediatr Crit Care Med 2013; 14: 593–600.
    1. Tunks RD, Barker PC, Benjamin DK Jr, Cohen‐Wolkowiez M, Fleming GA, Laughon M, Li JS, Hill KD. Sildenafil exposure and hemodynamic effect after Fontan surgery. Pediatr Crit Care Med 2014; 15: 28–34.
    1. Ciliberti P, Schulze‐Neick I, Giardini A. Modulation of pulmonary vascular resistance as a target for therapeutic interventions in Fontan patients: focus on phosphodiesterase inhibitors. Future Cardiol 2012; 8: 271–284.
    1. Llamas JP, Szkutnik M, Fiszer R, Bialkowski J. Treatment of elevated pulmonary artery pressure in a child after Glenn procedure: transcatheter closure of pulmonary artery banding with subsequent sildenafil therapy. Kardiol Pol 2012; 70: 201–203.
    1. Giordano R, Palma G, Poli V, Palumbo S, Russolillo V, Cioffi S, Mucerino M, Mannacio VA, Vosa C. First experience with sildenafil after Fontan operation: short‐term outcomes. J Cardiovasc Med (Hagerstown) 2015; 16: 552–555.
    1. Park IS. Efficacy of pulmonary vasodilator therapy in patients with functionally single ventricle. Int Heart J 2015; 56: S26–S30.
    1. Reinhardt Z, Uzun O, Bhole V, Ofoe V, Wilson D, Onuzo O, Wright JG, Stumper O. Sildenafil in the management of the failing Fontan circulation. Cardiol Young 2010; 20: 522–525.
    1. Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double‐blind, placebo‐controlled, crossover trial. Circulation 2011; 123: 1185–1193.
    1. Miranda WR, Borlaug BA, Hagler DJ, Connolly HM, Egbe AC. Haemodynamic profiles in adult Fontan patients: associated haemodynamics and prognosis. Eur J Heart Fail 2019; 21: 803–809.
    1. Amedro P, Basquin A, Gressin V, Clerson P, Jais X, Thambo JB, Guerin P, Cohen S, Bonnet D. Health‐related quality of life of patients with pulmonary arterial hypertension associated with CHD: the multicentre cross‐sectional ACHILLE study. Cardiol Young 2016; 26: 1250–1259.
    1. Poggio R, Arazi HC, Giorgi M, Miriuka SG. Prediction of severe cardiovascular events by VE/VCO2 slope versus peak VO2 in systolic heart failure: a meta‐analysis of the published literature. Am Heart J 2010; 160: 1004–1014.
    1. Amedro P, Picot MC, Moniotte S, Dorka R, Bertet H, Guillaumont S, Barrea C, Vincenti M, de la Villeon G, Bredy C, Soulatges C, Voisin M, Matecki S, Auquier P. Correlation between cardio‐pulmonary exercise test variables and health‐related quality of life among children with congenital heart diseases. Int J Cardiol 2016; 203: 1052–1060.
    1. Amedro P, Gavotto A, Legendre A, Lavastre K, Bredy C, De La Villeon G, Matecki S, Ladeveze M, Bajolle F, Bosser G, Bouvaist H. Impact of a centre and home‐based cardiac rehabilitation program on the quality of life of teenagers and young adults with congenital heart disease: The QUALI‐REHAB study rationale, design and methods. Int J Cardiol 2018; 283:112‐118.
    1. Houyel L, To‐Dumortier NT , Lepers Y, Petit J, Roussin R, Ly M, Lebret E, Fadel E, Hörer J, Hascoët S. Heart transplantation in adults with congenital heart disease. Arch Cardiovasc Dis 2017; 110: 346–353.
    1. Butts RJ, Chowdhury SM, Baker GH, Bandisode V, Savage AJ, Atz AM. Effect of Sildenafil on pressure‐volume loop measures of ventricular function in Fontan patients. Pediatr Cardiol 2016; 37: 184–191.
    1. Jackson KW, Butts RJ, Svenson AJ, McQuinn TC, Atz AM. Response to a single dose of sildenafil in single‐ventricle patients: an echocardiographic evaluation. Pediatr Cardiol 2013; 34: 1739–1742.
    1. Goldberg DJ, French B, Szwast AL, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr Cardiol 2012; 33: 689–696.
    1. Schuuring MJ, Vis JC, van Dijk AP, van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, de Bruin‐Bon RH, Mulder BJ, Bouma BJ. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail 2013; 15: 690–698.
    1. Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang MK, Colorado P, Meier C, Busse D, Benza RL. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase‐5 inhibitors. Eur Respir J 2017; 50: 1602425.
    1. Friehs I, Dacar D, Gamillscheg A, Machler H, Anelli‐Monti M, Oberwalder P, Beitzke A, Metzler H, Rigler B. Total cavo‐pulmonary connection as a therapeutic principle in anatomical and functional univentricular heart. Wien Klin Wochenschr 1995; 107: 714–717.
    1. Cai J, Su Z, Shi Z, Zhou Y, Xu Z, Xu Z, Yang Y. Nitric oxide and milrinone: combined effect on pulmonary circulation after Fontan‐type procedure: a prospective, randomized study. Ann Thorac Surg 2008; 86: 882–888 discussion ‐8.
    1. Wang W, Hu X, Liao W, Rutahoile WH, Malenka DJ, Zeng X, Yang Y, Feng P, Wen L, Huang W. The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta‐analysis of randomized controlled trials. Pulm Circ 2019; 9: 2045894018790450.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit